![](https://hitconsultant.net/wp-content/uploads/2024/05/image-2-1500x613.png)
What you should know:
– PorterLinqa leader in the field of wearable health monitoring, announced a strategic plan acquisition of AMI Cardiac Monitoring, LLCexperienced player in ambulatory cardiac monitoring.
– The acquisition, coupled with a recent $6.7 million funding round, allows WearLinq to significantly expand access to its innovative eWave 6-lead ECG monitor and revolutionize the fight against atrial fibrillation (AFib ), which recently received 510(k) clearance from the FDA.
Fighting the Silent Threat of AFib
Atrial fibrillation, an irregular heart rhythm, affects one in three people during their lifetime. This increases the risk of stroke fivefold and often leads to heart failure. Yet current diagnostic methods overlook a significant portion of cases, with more than 30% of patients receiving false negatives and needing to retest within six months.
WearLinq eWave: a powerful tool for early detection
WearLinq's eWave 6-lead ECG device seeks to fill these gaps. This wearable technology provides cardiologists with a detailed, multi-dimensional view of the heart, ensuring accurate P-wave detection and exceptional ECG clarity. Here's what sets eWave apart:
- Patient comfort: Designed for comfort and minimal intrusion, the eWave allows patients to maintain their daily routines while undergoing cardiac monitoring.
- Long-term monitoring: The device works seamlessly with a smartphone for extended monitoring periods. A convenient charging case, similar to AirPods, ensures continuous operation.
- Advanced data analysis: Integrated with an industry-leading cloud platform, eWave provides near real-time data analysis and actionable insights to healthcare providers.
- Adhesive patches imitating skin: WearLinq's patent-pending adhesive patches ensure secure, comfortable wear.
Joe Knight appointed to board of directors
The acquisition of AMI Cardiac Monitoring expands WearLinq's ability to offer its eWave technology in all 50 states and provide expanded clinical services. Additionally, WearLinq welcomes industry veteran Joe Knight, co-inventor of iRhythm's ZioPatch, to its board of directors. Knight's expertise will be invaluable as WearLinq continues to innovate and revolutionize the cardiac monitoring landscape.
"We are excited to join forces with WearLinq, a company at the forefront of cardiac monitoring innovation. This partnership aligns perfectly with our mission to provide exceptional diagnostic services," said Dorothy Glodek, Founder of AMI Cardiac Monitoring, LLC. "By integrating WearLinq's advanced 6-lead ECG technology with our extensive clinical expertise, we can offer unparalleled cardiac care to patients nationwide. Together, we are set to revolutionize the field of ambulatory cardiac monitoring, ensuring more accurate diagnoses and improved patient outcomes."